Teva Pharmaceutical Industries Limited (TEV) - Total Liabilities
Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEV) has total liabilities worth €31.81 Billion EUR (≈ $37.19 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Teva Pharmaceutical Industries Limited (TEV) equity growth momentum to track the company's year-over-year net asset growth rate.
Teva Pharmaceutical Industries Limited - Total Liabilities Trend (2015–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited's total liabilities have evolved over time, based on quarterly financial data. See TEV cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Teva Pharmaceutical Industries Limited Competitors by Total Liabilities
The table below lists competitors of Teva Pharmaceutical Industries Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telefonaktiebolaget LM Ericsson B ADR
NASDAQ:ERIC
|
USA | $186.22 Billion |
|
Advanced Info Service Public Company Limited
BK:ADVANC
|
Thailand | ฿312.99 Billion |
|
Cez A.S.
PR:CEZ
|
Czech Republic | Kč622.27 Billion |
|
Trip.com Group Ltd ADR
NASDAQ:TCOM
|
USA | $100.60 Billion |
|
Wanhua Chemical Group Co Ltd
SHG:600309
|
China | CN¥211.99 Billion |
|
SSE PLC ADR LS-50 1
F:SCTA
|
Germany | €17.23 Billion |
|
United Microelectronics Corporation
F:UMCB
|
Germany | €193.20 Billion |
|
Vodafone Group Plc
MX:VODN
|
Mexico | MX$75.55 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Teva Pharmaceutical Industries Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TEV market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Teva Pharmaceutical Industries Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Teva Pharmaceutical Industries Limited (2015–2025)
The table below shows the annual total liabilities of Teva Pharmaceutical Industries Limited from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €32.83 Billion ≈ $38.39 Billion |
-2.30% |
| 2024-12-31 | €33.61 Billion ≈ $39.29 Billion |
-4.94% |
| 2023-12-31 | €35.35 Billion ≈ $41.33 Billion |
+0.11% |
| 2022-12-31 | €35.31 Billion ≈ $41.29 Billion |
-3.04% |
| 2021-12-31 | €36.42 Billion ≈ $42.58 Billion |
-7.98% |
| 2020-12-31 | €39.58 Billion ≈ $46.27 Billion |
-6.67% |
| 2019-12-31 | €42.41 Billion ≈ $49.58 Billion |
-5.53% |
| 2018-12-31 | €44.89 Billion ≈ $52.48 Billion |
-13.46% |
| 2017-12-31 | €51.87 Billion ≈ $60.64 Billion |
-10.41% |
| 2016-12-31 | €57.90 Billion ≈ $67.69 Billion |
+138.20% |
| 2015-12-31 | €24.31 Billion ≈ $28.42 Billion |
-- |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more